Ascentage Pharma (AAPG, Financial) has achieved significant recognition with the inclusion of two of its proprietary drugs in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. The company's experimental Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has been recommended for the first time in the CSCO Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. This recommendation supports its use as a monotherapy for patients experiencing relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Moreover, olverembatinib, Ascentage's advanced tyrosine kinase inhibitor, has received an upgraded recommendation in the CSCO Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescents. It is now a Level I recommended treatment for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who have the T315I BCR-ABL1 kinase domain mutation. Additionally, olverembatinib retained its recommendations in the CSCO Guidelines for the Diagnosis and Treatment of Hematological Malignancies.
Labeled as the world’s second Bcl-2 inhibitor to advance to the New Drug Application stage, along with being the first China-developed Bcl-2 inhibitor to achieve NDA submission and Priority Review designation in China, lisaftoclax’s inclusion in these guidelines highlights its promising clinical potential and supports Ascentage Pharma's innovative contributions to oncology therapeutics.
